Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates

G. Folprecht, Axel F Grothey, Steven Robert Alberts, H. R. Raab, C. H. Köhne

Research output: Contribution to journalArticle

515 Citations (Scopus)

Abstract

Background: Long-term survival is reported in patients with liver metastases of colorectal cancer. Recently, an increased number of reports on liver resection following neoadjuvant chemotherapy in patients with initially unresectable liver metastases has been published. Methods: We analysed all published or presented trials and retrospective studies that report the rate of objective response and the rate of resection of initially unresectable metastases to correlate objective response and the rate of resection of metastases. Results: In studies that enrolled patients with metastases confined to the liver, 24-54% of patients were resected following chemotherapy, compared to 1-26% of patients in trials that included non-selected patients with metastatic colorectal cancer. A strong correlation was found between response rates and the resection rate in studies with patients with isolated liver metastases (r = 0.96, P = 0.002). Likewise, in studies with non-selected patients, the resection rate of metastases also was associated with the objective response rate (r = 0.74, <0.001). Conclusions: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases. Resectability is a novel endpoint focusing on the curative potential of treatment compared with classical endpoints of response or progression-free survival that are important if palliation is the aim. Therefore, patients with potentially resectable liver metastases should be investigated in special trials and interdisciplinary teams.

Original languageEnglish (US)
Pages (from-to)1311-1319
Number of pages9
JournalAnnals of Oncology
Volume16
Issue number8
DOIs
StatePublished - Aug 2005

Fingerprint

Neoadjuvant Therapy
Neoplasm Metastasis
Liver
Neoplasms
Drug Therapy
Colorectal Neoplasms
Patient Selection
Disease-Free Survival
Retrospective Studies
Survival

Keywords

  • Colorectal cancer
  • Liver metastases
  • Neoadjuvant chemotherapy
  • Resection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neoadjuvant treatment of unresectable colorectal liver metastases : Correlation between tumour response and resection rates. / Folprecht, G.; Grothey, Axel F; Alberts, Steven Robert; Raab, H. R.; Köhne, C. H.

In: Annals of Oncology, Vol. 16, No. 8, 08.2005, p. 1311-1319.

Research output: Contribution to journalArticle

@article{93a6d220620747909c4844e07acf37c1,
title = "Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates",
abstract = "Background: Long-term survival is reported in patients with liver metastases of colorectal cancer. Recently, an increased number of reports on liver resection following neoadjuvant chemotherapy in patients with initially unresectable liver metastases has been published. Methods: We analysed all published or presented trials and retrospective studies that report the rate of objective response and the rate of resection of initially unresectable metastases to correlate objective response and the rate of resection of metastases. Results: In studies that enrolled patients with metastases confined to the liver, 24-54{\%} of patients were resected following chemotherapy, compared to 1-26{\%} of patients in trials that included non-selected patients with metastatic colorectal cancer. A strong correlation was found between response rates and the resection rate in studies with patients with isolated liver metastases (r = 0.96, P = 0.002). Likewise, in studies with non-selected patients, the resection rate of metastases also was associated with the objective response rate (r = 0.74, <0.001). Conclusions: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases. Resectability is a novel endpoint focusing on the curative potential of treatment compared with classical endpoints of response or progression-free survival that are important if palliation is the aim. Therefore, patients with potentially resectable liver metastases should be investigated in special trials and interdisciplinary teams.",
keywords = "Colorectal cancer, Liver metastases, Neoadjuvant chemotherapy, Resection",
author = "G. Folprecht and Grothey, {Axel F} and Alberts, {Steven Robert} and Raab, {H. R.} and K{\"o}hne, {C. H.}",
year = "2005",
month = "8",
doi = "10.1093/annonc/mdi246",
language = "English (US)",
volume = "16",
pages = "1311--1319",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Neoadjuvant treatment of unresectable colorectal liver metastases

T2 - Correlation between tumour response and resection rates

AU - Folprecht, G.

AU - Grothey, Axel F

AU - Alberts, Steven Robert

AU - Raab, H. R.

AU - Köhne, C. H.

PY - 2005/8

Y1 - 2005/8

N2 - Background: Long-term survival is reported in patients with liver metastases of colorectal cancer. Recently, an increased number of reports on liver resection following neoadjuvant chemotherapy in patients with initially unresectable liver metastases has been published. Methods: We analysed all published or presented trials and retrospective studies that report the rate of objective response and the rate of resection of initially unresectable metastases to correlate objective response and the rate of resection of metastases. Results: In studies that enrolled patients with metastases confined to the liver, 24-54% of patients were resected following chemotherapy, compared to 1-26% of patients in trials that included non-selected patients with metastatic colorectal cancer. A strong correlation was found between response rates and the resection rate in studies with patients with isolated liver metastases (r = 0.96, P = 0.002). Likewise, in studies with non-selected patients, the resection rate of metastases also was associated with the objective response rate (r = 0.74, <0.001). Conclusions: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases. Resectability is a novel endpoint focusing on the curative potential of treatment compared with classical endpoints of response or progression-free survival that are important if palliation is the aim. Therefore, patients with potentially resectable liver metastases should be investigated in special trials and interdisciplinary teams.

AB - Background: Long-term survival is reported in patients with liver metastases of colorectal cancer. Recently, an increased number of reports on liver resection following neoadjuvant chemotherapy in patients with initially unresectable liver metastases has been published. Methods: We analysed all published or presented trials and retrospective studies that report the rate of objective response and the rate of resection of initially unresectable metastases to correlate objective response and the rate of resection of metastases. Results: In studies that enrolled patients with metastases confined to the liver, 24-54% of patients were resected following chemotherapy, compared to 1-26% of patients in trials that included non-selected patients with metastatic colorectal cancer. A strong correlation was found between response rates and the resection rate in studies with patients with isolated liver metastases (r = 0.96, P = 0.002). Likewise, in studies with non-selected patients, the resection rate of metastases also was associated with the objective response rate (r = 0.74, <0.001). Conclusions: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases. Resectability is a novel endpoint focusing on the curative potential of treatment compared with classical endpoints of response or progression-free survival that are important if palliation is the aim. Therefore, patients with potentially resectable liver metastases should be investigated in special trials and interdisciplinary teams.

KW - Colorectal cancer

KW - Liver metastases

KW - Neoadjuvant chemotherapy

KW - Resection

UR - http://www.scopus.com/inward/record.url?scp=23844448040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844448040&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi246

DO - 10.1093/annonc/mdi246

M3 - Article

C2 - 15870084

AN - SCOPUS:23844448040

VL - 16

SP - 1311

EP - 1319

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -